Navigation Links
ECLINSO Announces Partnership with XClinical
Date:3/2/2012

dation plan with a click of a button- all CDISC ODM compliant from the start. The solution accelerates the whole clinical trial process and thus saves time and money.

Combined with trialforce, MARVIN offers unparalleled visibility, exception management, and analysis of information from clinical trials, enabling trial sponsors and managers to make critical decisions during and throughout a trial. Integration and interoperability through other Trialforce solutions, such as IVR and ePRO, can be provided easily and seamlessly. 

"ECLINSOis extremely pleased to be able to offer MARVIN. XClinical shares our philosophy of providing innovative solutions based on industry standards, which enables interoperability within our trialforce platform. The convergence of cloud-based solutions such as Trialforce with MARVIN will significantly improve clinical trial efficiency while reducing costs."  Said Frank Pijpers, CEO of ECLINSO.

"XClinicalis delighted to have reached this partnership agreement with ECLINSO.  It enables us to offer an enterprise-level delivery and support channel for our solutions." Said Philippe Verplancke, CEO of XClinical. 

About ECLINSO (www.eclinso.com)

ECLINSO is an innovative provider of Clinical Technology solutions and global support services to enhance the conduct of clinical trials. Our international reputation combined with our deep industry understanding and innovative approach through trialforce is setting the benchmark for the use of cloud-based solutions for clinical trials. Through trialforce we deliver an innovative standards, affordable, scalable and easy-to-use platform that enables sponsors and CRO's to rapidly deploy an integrated EDC/Data Management/eClinical suite. The solution is based on an uncomplicated SaaS pricing model, that offers minimal upfront costs and significantly lower initi
'/>"/>

SOURCE ECLINSO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... 29 AstraZeneca (NYSE: AZN ) announced today ... Delaware , has found that the substance patent protecting CRESTOR (RE37,314 – the ... no inequitable conduct was committed by any Shionogi employee. The court also held ... , , ...
... CINCINNATI, Ohio , June 29 Dr. Harry ... invited speaker and panel discussion participant at the 2010 Central Regional Meeting ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants ... traditional chemical disciplines.   , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:12/19/2014)... death from "rat-bite fever" of a 10-year-old San Diego boy ... a report from the U.S. Centers for Disease Control and ... illness that should be considered in persons with rash, fever ... is reported," said a team led by Dr. Jessica Adam ... in the report occurred in August of 2013. Adam,s ...
(Date:12/19/2014)... Randy Dotinga ... News) -- Common painkillers, including ibuprofen, might slightly reduce ... researchers say. Use of ibuprofen (Advil, Motrin) and ... cell skin cancer by 15 percent, the researchers concluded ... is usually caused by sun exposure. ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... 2014 While countless companies tempt patients to ... the potential dangers of their purchase. Not only is the ... qualified doctor, but patients who buy hCG online are typically ... is actually no real hCG present. Illegal internet hCG is ... no safety standards and may contain unknown fillers that can ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
Breaking Medicine News(10 mins):Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... DDS, and her staff will be racing to save lives ... of Baltimore,s 2009 Susan G. Komen Race for the Cure. ... Team Chincheck has raised more than $4,700 for breast cancer ... affected by breast cancer and witnessing their strength and courage ...
... some parents may be lukewarm to the H1N1 vaccination, ... of Southern California,s largest integrated, comprehensive healthcare organizations, reports ... access to the vaccine. In response, Lakeside Community Healthcare ... patients direct access to the information they need to ...
... ... tourism industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. ... ... , a global health care company in the emerging medical tourism industry, announced the addition ...
... Oct. 14 Usinas,Siderurgicas de Minas Gerais S.A. - USIMINAS (OTC: USNZY) (BOVESPA: USIM3,USIM5, USIM6) ... Third Quarter 2009 Results Conference Call. Results will be, ... after Bovespa,s trading session., ... third quarter 2009 results, ...
... Peter Sheldon, Vice President of Operations for Coverall Health-Based ... will be a featured speaker at the Professional Retail ... on October 14-15 at The Fairmont Hotel in Dallas, ... Best in Your Business with Best Practices." Sheldon will ...
... Terumo ... the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual ... , ... Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today ...
Cached Medicine News:Health News:Team Chincheck Goes Miles for Smiles 2Health News:Leading Southern California Physicians Report Patient Fears About Complexities of Flu Season 2Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Third Quarter 2009 Results Webcast 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: